Limited impact of short-term disruptions, growth momentum to continue in FY 23
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Company expects strong organic growth in sales, EBITDA in 2022
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
This has further strengthened its manufacturing presence in the United States of America
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
High level of vaccine efficacy maintained over a 6-month period of surveillance
Subscribe To Our Newsletter & Stay Updated